

Es-Propacli

Paclitaxel Nanoparticle Injection 100mg/vial

A New Standard of Care



With Improved Efficacy & Safety

An effective and well-tolerated treatment of patients affected by MBC¹

The drug showed an improved tolerability profile¹

Proven to be an effective and safe therapeutic option in patients with MBC¹

Es-Propacli - Nanoparticle-based delivery system

- Lowering its toxicity²
- Increasing its circulation half-life²
- Exhibiting improved pharmacokinetic profiles²
- Demonstrating better patient compliance²

Indication,

- Metastatic breast cancer
- Non-small cell lung cancer
- Pancreas cancer
- Ovarian cancer
- Cancer of the fallopian tubes
- Primary peritoneal cancer



1. <https://doi.org/10.2147/OTT.S191519>

2. J NanomedNanotechnol. 2013 Feb 18; 4(2): 1000164, doi: 10.4172/2157-7439.1000164

Es Soratos

Sorafenib 200mg Tablets

« An Extended Spectrum TKI »



Expanding the reach & impact to save more Lives...!!!

HCC is the 5th most common cancer and the 3rd leading cause of cancer-related mortality worldwide, accounting for approximately 745,500 deaths each year¹

Cirrhosis is the most important risk factor for HCC, with approximately 80% of HCC cases developing in patients with liver cirrhosis²

The estimated number of cases per year in India is approximately close to 22,000 with a similar mortality³

Indications

HCC


- Sorafenib is the only agent approved for first-line treatment of patients with advanced HCC
- Sorafenib is the only systemic treatment that has been shown to increase overall survival in patients with advanced HCC

RCC

- Sorafenib is approved as a *second-line agent* for the treatment of metastatic RCC, it prolongs PFS in patients with advanced clear cell RCC in whom previous therapy has failed

Thyroid Cancer

- Sorafenib was approved by the FDA for the treatment of locally recurrent or metastatic, progressive differentiated thyroid carcinoma (DTC) The Phase 3 DECISION trial showed significant improvement in PFS but not in OS.



1. Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87-108. doi: 10.3322/caac.21262. [PubMed] [CrossRef] [Google Scholar]

2. London WT MK. Cancer epidemiology and prevention. 3rd edition. New York: Oxford University Press, 2006

3. Kumar R, Saraswat MK, Sharma BC, et al. Characteristics of hepatocellular carcinoma in India: a retrospective analysis of 191 cases. QJM 2008;101:479-85. [PubMed]